Current Report Filing (8-k)
September 15 2021 - 09:10AM
Edgar (US Regulatory)
0001174940 false 0001174940 2021-09-15
2021-09-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange
Act of 1934.
Date of
Report:
September 15, 2021
(Date of
earliest event reported)
Oragenics, Inc.
(Exact
name of registrant as specified in its charter)
|
FL |
|
001-32188 |
|
59-3410522 |
|
(State or
other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
Number)
|
|
4902 Eisenhower Boulevard,
Suite 125
Tampa,
FL
|
|
33634 |
|
(Address
of principal executive offices) |
|
(Zip
Code) |
813-286-7900
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if changed since last
report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
|
Title of
each class |
|
Trading
Symbol(s) |
|
Name of
each exchange on which registered |
|
Common Stock |
|
OGEN |
|
NYSE American |
Indicate by
check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01
Other Information
On September
15, 2021, Oragenics, Inc. (“Oragenics” or the “Company”) issued a
press release (the “Press Release”) regarding the initiation of a
study to evaluate the immunogenicity and viral load reduction
impact of its SARS-CoV-2 vaccine candidate in a hamster challenge
study.
A copy of
the Press Release is attached hereto as Exhibit 99.1.
Item 9.01
Financial Statements and Exhibits
(d)
Exhibits
SIGNATURES
In
accordance with the requirements of the Exchange Act, the
registrant caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized on this 15th day
of September, 2021.
|
|
ORAGENICS,
INC.
(Registrant)
|
|
|
|
|
|
BY: |
/s/
Michael Sullivan |
|
|
|
Michael
Sullivan
Interim
Principal Executive Officer
and Chief
Financial Officer
|
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Jun 2022 to Jul 2022
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Jul 2021 to Jul 2022
